FZ-AD005
FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer[1].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fz-ad005.html
Purity
97.27
Smiles
[FZ-AD005]
References & Citations
[1]Qingsong Guo, et al. FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28;23 (10) :1367–1377.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Badge
Hot
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items